SCHEMBL6296097

SCHEMBL6296097

CC(C)(C)OC(=O)NC[C@@H]1CN(c2ccc3c(c2)CN(C(=O)OCc2ccccc2)CC3)C(=O)O1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 20/20 0.56
SIGMAR1 Q99720 20/20 0.56
HRH2 P25021 4/20 0.51
HTR2C P28335 4/20 0.51
HRH1 P35367 4/20 0.51
ADRA2A P08913 3/20 0.51
ADRA2B P18089 3/20 0.51
HRH3 Q9Y5N1 3/20 0.51
HTR1A P08908 3/20 0.51
HTR2A P28223 3/20 0.51
HTR2B P41595 3/20 0.51
DRD3 P35462 2/20 0.51
CHRM5 P08912 2/20 0.51
ADRA1D P25100 2/20 0.51
CHRM4 P08173 1/20 0.51
ADRA1A P35348 1/20 0.51
ADRA1B P35368 1/20 0.51
HTR5A P47898 1/20 0.51
HTR1E P28566 3/20 0.51
HTR1B P28222 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6296095 1.00 TMEM97 (0.56) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL6291704 0.97 TMEM97 (0.56) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL6291702 0.97 TMEM97 (0.56) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL6292471 0.87 TMEM97 (0.60) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL6292486 0.85 TMEM97 (0.52) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL5725604 0.83 MAOB (0.56)
SCHEMBL5725608 0.83 MAOB (0.56)
SCHEMBL6291313 0.82 TMEM97 (0.61) TMEM97SIGMAR1HRH2HTR2CHRH1
SCHEMBL6963692 0.82 F10 (0.43)
SCHEMBL6963698 0.82 F10 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972286-B2 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle PHARMACIA AND UPJOHN COMPANY (US) 2005-12-06 US disclosed
US-20040186293-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle JOHNSON PAUL D (US) 2004-09-23 US disclosed
US-20040176609-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle JOHNSON PAUL D (US) 2004-09-09 US disclosed
EP-1337530-A1 OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS Pharmacia & Upjohn Company (US) 2003-08-27 EP disclosed
US-20020133021-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle PHARMACIA & UPJOHN COMPANY 2002-09-19 US disclosed
WO-2002059115-A1 OXAZOLIDINONES HAVING A BENZANNULATED 6-OR 7-MEMBERED HETEROCYCLE AS ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020133021-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle OXA1L, CDK16, MT-ND6 TMEM97 2993/4885SIGMAR1 3334/4885HRH2 2235/4885
US-20040186293-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle OXA1L, CDK16, MT-ND6 TMEM97 2993/4885SIGMAR1 3334/4885HRH2 2235/4885
US-20040176609-A1 Oxazolidinones having a benzannulated 6- or 7-membered heterocycle OXA1L, CDK16, MT-ND6 TMEM97 2993/4885SIGMAR1 3334/4885HRH2 2235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.